CMG Pharmaceutical Co. Ltd
CMG Pharmaceutical Co., Ltd., a pharmaceutical company, develops and sells oral thin film (OTF) pharmaceuticals in South Korea. It offers Tadalafil OTF products for erectile dysfunction; Entecavir OTF products to treat hepatitis type B; Aripiprazole OTF products for schizophrenia; and Montelukast OTF products to treat asthma and allergic rhinitis. CMG Pharmaceutical Co. Ltd. has a strategic colla… Read more
CMG Pharmaceutical Co. Ltd (058820) - Net Assets
Latest net assets as of September 2025: ₩204.41 Billion KRW
Based on the latest financial reports, CMG Pharmaceutical Co. Ltd (058820) has net assets worth ₩204.41 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩307.70 Billion) and total liabilities (₩103.30 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩204.41 Billion |
| % of Total Assets | 66.43% |
| Annual Growth Rate | 19.83% |
| 5-Year Change | 4.64% |
| 10-Year Change | 304.94% |
| Growth Volatility | 38.78 |
CMG Pharmaceutical Co. Ltd - Net Assets Trend (2011–2024)
This chart illustrates how CMG Pharmaceutical Co. Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CMG Pharmaceutical Co. Ltd (2011–2024)
The table below shows the annual net assets of CMG Pharmaceutical Co. Ltd from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩189.54 Billion | -0.36% |
| 2023-12-31 | ₩190.23 Billion | +2.85% |
| 2022-12-31 | ₩184.95 Billion | +0.14% |
| 2021-12-31 | ₩184.70 Billion | +1.97% |
| 2020-12-31 | ₩181.13 Billion | +0.54% |
| 2019-12-31 | ₩180.16 Billion | +73.26% |
| 2018-12-31 | ₩103.98 Billion | +6.16% |
| 2017-12-31 | ₩97.94 Billion | -3.13% |
| 2016-12-31 | ₩101.11 Billion | +116.01% |
| 2015-12-31 | ₩46.81 Billion | -4.48% |
| 2014-12-31 | ₩49.00 Billion | +0.01% |
| 2013-12-31 | ₩49.00 Billion | +55.10% |
| 2012-12-31 | ₩31.59 Billion | +75.17% |
| 2011-12-31 | ₩18.03 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to CMG Pharmaceutical Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 635.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩13.89 Billion | 7.33% |
| Common Stock | ₩69.45 Billion | 36.64% |
| Other Components | ₩106.20 Billion | 56.03% |
| Total Equity | ₩189.54 Billion | 100.00% |
CMG Pharmaceutical Co. Ltd Competitors by Market Cap
The table below lists competitors of CMG Pharmaceutical Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tethys Oil AB
ST:TETY
|
$127.55 Million |
|
SIERRA MADRE GOLD AND SIL
F:409
|
$127.57 Million |
|
Caswell Inc
TW:6416
|
$127.60 Million |
|
Sichuan Langsha Holding Ltd
SHG:600137
|
$127.61 Million |
|
Audix Corp
TW:2459
|
$127.51 Million |
|
Guan Chong Bhd
KLSE:5102
|
$127.50 Million |
|
Frontera Energy Corp
PINK:FECCF
|
$127.48 Million |
|
i-SENS Inc
KQ:099190
|
$127.37 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CMG Pharmaceutical Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 190,232,688,060 to 189,542,119,220, a change of -690,568,840 (-0.4%).
- Net income of 2,694,712,070 contributed positively to equity growth.
- Other factors decreased equity by 3,385,280,910.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩2.69 Billion | +1.42% |
| Other Changes | ₩-3.39 Billion | -1.79% |
| Total Change | ₩- | -0.36% |
Book Value vs Market Value Analysis
This analysis compares CMG Pharmaceutical Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.25x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.97x to 1.25x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩865.13 | ₩1702.00 | x |
| 2017-12-31 | ₩836.68 | ₩1702.00 | x |
| 2018-12-31 | ₩888.26 | ₩1702.00 | x |
| 2019-12-31 | ₩1297.11 | ₩1702.00 | x |
| 2020-12-31 | ₩1304.11 | ₩1702.00 | x |
| 2021-12-31 | ₩1329.83 | ₩1702.00 | x |
| 2022-12-31 | ₩1331.63 | ₩1702.00 | x |
| 2023-12-31 | ₩1369.64 | ₩1702.00 | x |
| 2024-12-31 | ₩1364.67 | ₩1702.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CMG Pharmaceutical Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.42%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.72%
- • Asset Turnover: 0.33x
- • Equity Multiplier: 1.60x
- Recent ROE (1.42%) is above the historical average (0.97%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 0.60% | 1.45% | 0.36x | 1.14x | ₩-4.60 Billion |
| 2014 | 0.32% | 0.69% | 0.39x | 1.19x | ₩-4.74 Billion |
| 2015 | -7.80% | -13.50% | 0.48x | 1.21x | ₩-8.33 Billion |
| 2016 | 1.71% | 5.24% | 0.30x | 1.10x | ₩-8.38 Billion |
| 2017 | 2.89% | 6.83% | 0.38x | 1.12x | ₩-6.96 Billion |
| 2018 | 5.83% | 12.16% | 0.44x | 1.10x | ₩-4.33 Billion |
| 2019 | 1.69% | 5.20% | 0.30x | 1.07x | ₩-14.96 Billion |
| 2020 | 0.12% | 0.33% | 0.33x | 1.08x | ₩-17.90 Billion |
| 2021 | 1.71% | 4.56% | 0.35x | 1.08x | ₩-15.30 Billion |
| 2022 | -0.21% | -0.47% | 0.39x | 1.15x | ₩-18.88 Billion |
| 2023 | 3.39% | 6.87% | 0.39x | 1.27x | ₩-12.57 Billion |
| 2024 | 1.42% | 2.72% | 0.33x | 1.60x | ₩-16.26 Billion |
Industry Comparison
This section compares CMG Pharmaceutical Co. Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $185,563,423,740
- Average return on equity (ROE) among peers: 1.60%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CMG Pharmaceutical Co. Ltd (058820) | ₩204.41 Billion | 0.60% | 0.51x | $127.53 Million |
| Dongwha Pharm.Co.Ltd (000020) | $229.73 Billion | 2.15% | 0.36x | $75.32 Million |
| Yuhan Corp. (000100) | $323.58 Billion | 10.19% | 0.72x | $4.21 Billion |
| Yuyu Pharma Inc (000227) | $128.69 Billion | -1.72% | 0.50x | $26.44 Million |
| Ildong Holdings Co Ltd (000230) | $66.98 Billion | 10.88% | 1.80x | $49.55 Million |
| Samil Pharm (000520) | $62.87 Billion | 0.00% | 0.77x | $110.58 Million |
| Donga Socio Holdings (000640) | $328.69 Billion | 10.58% | 1.17x | $206.35 Million |
| Jw Pharmac (001060) | $223.83 Billion | 0.28% | 1.65x | $278.34 Million |
| JW Pharmaceutical Corp (001067) | $265.44 Billion | 13.94% | 1.43x | $489.75 Million |
| Samsung Pharm (001360) | $77.58 Billion | -31.98% | 0.20x | $65.82 Million |
| Ahn-Gook Pharmaceutical Co. Ltd (001540) | $148.25 Billion | 1.71% | 0.47x | $27.39 Million |